← Back to catalogue

Toxoplasma IgG Microassay

FDA 510(k)

Class II (US FDA 510(k))

510(k) K863813

by Diamedix Corp.

Identifiers

510(k) Number
K863813 FDA 510(k)
FDA Product Code
LGD FDA 510(k)

Classification

Device Class
Class II FDA 510(k)
Legislation / Framework
21 CFR Part 866.3780 FDA 510(k)
Regulation Number
866.3780 FDA 510(k)
Advisory Committee
Microbiology FDA 510(k)
FDA Decision
SESE Substantially Equivalent FDA 510(k)

The Toxoplasma IgG Microassay is an Enzyme Linked Immunoabsorbent Assay (ELISA) designed for the detection and semi-quantitation of human IgG antibodies to Toxoplasma gondii in human serum. It functions as an indirect immunoassay to evaluate the immunological response to Toxoplasma gondii infection, aiding in the assessment of an individual’s immune status.

This device is supplied as a single-use diagnostic test kit and is intended for use in clinical microbiology laboratories. It requires no special storage conditions beyond refrigeration and is classified under FDA product code LGD (Laboratory Reagents, General and Other). The assay received FDA 510(k) clearance (K863813) under the Traditional 510(k) review pathway, with a decision of Substantially Equivalent to the predicate device.

This description and any FAQs above were generated automatically from registry data and have not been verified by the manufacturer or by deviCERTS. Always check the official registry entry and the manufacturer's instructions for use before relying on them. Sources consulted: TOXOPLASMA IGG MICROASSAY (K863813) — FDA 510(k) | Innolitics, TOXOPLASMA IGG MICROASSAY 510 (k) K863813 - FDA.report, PDF K863813 - Toxoplasma Igg Microassay, Diamedix Corp. — FDA 510 (k) clearances & recalls · 510k Monitor, Diamedix Corp. · DeviceClearance

Authorization Coverage (1 country)

Regulatory Authorizations

United States Active

FDA_510K

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Manufacturer
Diamedix Corp.

Sources (1)

  • FDA 510(k) K863813 24 fields · synced Sep 19, 2026